Hong Kong Stock Movement: CLOUDBREAK-B falls 18.85%, market concerns arise from extended lock-up period and shareholder holdings

Hong Kong Stock Movement CLOUDBREAK-B fell 18.85%. Based on recent news, On January 2, cornerstone investor FuCe Holdings voluntarily committed to extend the lock-up period. The lock-up period was extended from the originally scheduled January 3, 2026, to July 2, 2026, showing confidence in the company's future prospects, but the market reacted negatively, leading to a decline in stock price. On January 3, the company allocated and issued 1.785 million shares under the 2023 equity incentive plan. This move increased the number of circulating shares in the market, further depressing the stock price. On January 2, data from the Hong Kong Stock Exchange showed that CLOUDBREAK-B shareholders deposited shares into Guangfa Securities Hong Kong, with a market value of HKD 1.605 billion, accounting for 36.55%. This large-scale stock deposit raised market concerns about the company's future stock price performance, leading to a decline in stock price. The market holds a cautious attitude towards the company's future prospects, resulting in significant stock price fluctuations. Stocks with High Trading Volume in the Industry Innovent Biologics rose 2.92%. Based on recent key news: On January 3, the market size of China's innovative drug sector surpassed RMB 120 billion, tripling since 2019, demonstrating strong market potential. As a leading company in the innovative drug field, Innovent Biologics benefits from market recognition of innovative drugs, driving up its stock price. Source: Financial Annual. On January 3, multinational pharmaceutical companies increased transactions for cutting-edge innovative drugs in China, indicating international market confidence in Chinese innovative drugs. Innovent Biologics' R&D capabilities and market position were further solidified, resulting in a rise in stock price. Source: Financial Annual. On January 3, Innovent Biologics' Chief R&D Officer Qian Lei stated that China's biopharmaceutical market will gradually align with global standards, becoming mainstream in the pharmaceutical market. This optimistic outlook enhanced investor confidence, driving up the stock price. Source: Financial Annual. The innovative drug market has huge potential, with significant capital inflow. 3SBio rose 1.14%. Based on recent news: On January 2, CMB International released a research report indicating that the mainland's "14th Five-Year Plan" has set the tone, with the market entering a period of policy validation and profit recovery, and 3SBio was listed as one of the key stocks to watch in January. This news boosted market confidence, driving up the stock price. On January 4, the National Medical Products Administration announced that it would introduce more measures to promote the rapid development of innovative drugs in China, especially increasing support for new mechanisms and new targets. This favorable policy news further enhanced market expectations for 3SBio, promoting a rise in stock price. Favorable policies in the innovative drug industry have strengthened market confidence. BeiGene rose 2.76%. Based on recent key news: On January 4, the collaboration model between medical insurance and commercial insurance promoted market access for innovative drugs. Executives from multinational pharmaceutical companies pointed out that this model significantly improved patient accessibility, driving up BeiGene's stock price. Source: Zhitong Finance. On January 2, the inhibition of TIGIT protein is expected to assist the immune system in targeting cancer cells. This research progress has boosted market confidence in BeiGene, resulting in an increase in stock price Source: Caixin On January 4th, China's investment in innovative drug research and development continues to grow, with the number of clinical trials accounting for 30% of the global total. This trend has strengthened investors' optimistic expectations for BeiGene, driving up its stock price. Source: Zhitong Finance The innovative drug sector is experiencing high prosperity, with enormous market potential. Stocks ranked among the top in industry market capitalization Kangfang Biotech, up 0.62%, with a market capitalization of HKD 104.8 billion, has no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation